4 unknown, 1 completed, 1 recruiting. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 4, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Self Efficacy: new trials by email Literature Review of Self Efficacy trials Research Report on Self Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cognitive Remediation Intervention to Prepare for Transition of Care CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) - Sickle Cell Disease, Cognitive Impairment | Phase 2 | Recruiting | University of Alabama at Birmingham | 120 | 2022-07-01 | 2026-02-27 |
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients pazopanib - Self Efficacy, Adverse Drug Event | Phase 2 | Unknown | Southern China Urology Cancer Consortium | 86 | 2014-07-01 | 2014-12-24 |
| High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs Erlotinib or Gefitinib - Self Efficacy, Drug Toxicity | Phase 2 | Unknown | Anhui Medical University | 20 | 2013-10-01 | 2017-05-08 |
| Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer Ginsenoside Rg3 plus First-line Chemotherapy, First-line Chemotherapy - Self Efficacy | Phase 2 | Unknown | Hebei Tumor Hospital | 100 | 2012-12-01 | 2014-04-01 |
| Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg - Self Efficacy, Hepatitis C | Phase 2 / Phase 3 | Unknown | BioGeneric Pharma | 300 | 2010-11-01 | 2011-04-04 |
| Remegal Different Doses in Patients With Refractory Partial Seizures Remegal - Drug Safety, Normal Drug Tolerance | Phase 2 | Completed | Valexfarm | 60 | 2009-09-01 | 2017-05-11 |
Drug-Related Side Effects and Adverse Reactions (2) · Adolescent Behavior (1) · Anemia, Sickle Cell (1) · Carcinoma, Renal Cell (1) · Cognitive Dysfunction (1) · Health Behavior (1) · Hepatitis C (1)
Chemically-Induced Disorders (2) · Adenocarcinoma (1) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Behavior (1) · Blood-Borne Infections (1) · Carcinoma (1) · Cognition Disorders (1) · Communicable Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Flaviviridae Infections (1)
Erlotinib Hydrochloride (1) · Gefitinib (1) · ginsenoside Rg3 (1) · pazopanib (1)
Anhui Medical University (1) · BioGeneric Pharma (1) · Hebei Tumor Hospital (1) · Southern China Urology Cancer Consortium (1) · University of Alabama at Birmingham (1) · Valexfarm (1)
China (3) · Egypt (1) · Russia (1) · United States (1)
Dorogov Nikolay, MD, PhD (1) · Gamal Esmat, MD (1) · Mian Xie (1) · Mohamed Karim F Ashour, MD (1) · Wei Liu (1) · Yueyin Pan, PHD,MD (1)